Table 1.

Active trials of checkpoint inhibitor in ovarian cancer.

Drug	Antibody type∗	Notable side effects	Study (phase)
Anti-CTLA-4 antibodies
Ipilimumab	IgG1	Diarrhea, colitis, fatigue, transaminitis, hypophysitis.	I; II
Tremelimumab	IgG2	Diarrhea, fatigue, nausea, vomiting, anorexia, rash	I
Anti-PD-1 antibodies
Nivolumab	IgG4	Pneumonitis, lymphopenia, fatigue, diarrhea, hepatitis, renal insufficiency	I; II
Pembrolizumab	IgG4-kappa	Pneumonitis, fatigue, thyroid problems	I
Anti-PD-L1 antibodies
BMS-936559	IgG4	Fatigue, hyperglycemia, infusion reaction, endocrinopathies, adrenal insufficiency, myasthenia gravis	I; II
MEDI4736	IgG1-kappa	Diarrhea, fatigue, rash, vomiting	I
MPDL33280A	IgG4	Hyperglycemia, hypophysitis, pericardial effusion, fatigue	I
MSB0010718C	IgG1	Laboratory abnormalities, creatine kinase increase, myositis, myocarditis	I; II

^∗All fully human, except pembrolizumab which is a humanized IgG4-kappa.

Updated on February 28, 2015.